查詢結果分析
相關文獻
- The Relationships between Single Nucleotide Polymorphism and Outcome and Complications of Metastatic Colorectal Cancer Patients Who Underwent Irinotecan-based Chemotherapy
- Primary Peritoneal Cancer in Pregnancy with Multiple Metastases: A Case Report
- 動物基因組中的SNPs研究進展
- 乳牛之基因體選拔
- Submucosal Colonic Signet Ring Cell Carcinoma 5 Years after Surgical Resection of Gastric Cancer: Report of a Case
- 轉移性大腸癌病例之用藥探討
- Mitochondrial D-loop as Marker for Genetic Diversity Study of Giant Grouper (Epinephelus lanceolatus) Broodstocks in Taiwan
- NLRP3 Gene Polymorphisms and Systemic Lupus Erythematosus in Taiwan
頁籤選單縮合
題 名 | The Relationships between Single Nucleotide Polymorphism and Outcome and Complications of Metastatic Colorectal Cancer Patients Who Underwent Irinotecan-based Chemotherapy=在接受含Irrinotecan化療處方之轉移性大腸直腸癌病人中,單核苷酸多態性與預後及併發症之關聯性探討 |
---|---|
作 者 | 林琪鈞; 林宏鑫; 林春吉; 藍苑慈; 王煥昇; 楊純豪; 姜正愷; 陳維熊; 林資琛; 林楨國; 張世慶; | 書刊名 | 中華民國大腸直腸外科醫學會雜誌 |
卷 期 | 27:2 2016.06[民105.06] |
頁 次 | 頁74-82 |
分類號 | 416.245 |
關鍵詞 | 轉移性大腸癌; Irinotecan化療; 單核苷酸多態性; Metastatic colorectal cancer; Irinotecan-based chemotherapy; Single nucleotide polymorphism; |
語 文 | 英文(English) |
中文摘要 | 目的 於轉移性大腸癌病人接受化療之前,是否可以其單核苷酸多態性來分析其可能預後及嚴重併發症。方法 自2004 至2010 年間,統計台北榮民總醫院共有75 位病患,接受Irrinotecan 化療處方做為轉移性大腸癌的第一線治療,比較這些患者的12 種單核苷酸多態性,此篇文章針對這75 位病患的預後及嚴重併發症進行回顧性研究分析。結果 75 位病患,有48 位男性及27 位女性。平均使用irinotecan 治療的次數為9.58次。對比AA 基因型,ABCG2 A421C 在AC 及CC 基因型有較佳存活率 (p = .002)。TSG12C in 2R/3R 在GC 基因型有較高機率造成第三級以上的嗜中性白血球低下 (p= .048)。MTHFR C677T 在GC 基因型有較高機率造成第二級以上的丙氨酸轉胺酶升高(p = .044)。結論 研究特定的單核苷酸多態性,可以幫助我們在治療以irinotecan 做為轉移性大腸癌的化療病人,得到更好的預後以及避免嚴重併發症的發生。 |
英文摘要 | Background. Biomarkers for metastatic colorectal cancer may be checked before chemotherapy to achieve the best outcome and to avoid severe adverse effect. Material and Methods. Medical records from Jan 2004 to Dec 2010 were retrospectively reviewed, and 75 patients who underwent irinotecan-based chemotherapy as first-line chemotherapy for metastaticcolorectal cancer in Taipei Veterans General Hospital were identified. There were twelve-single nucleotide polymorphisms included. Among these patients, survival and adverse events including neutropenia, liver function impairment were analyzed. Results. There were 75 patients, 48 male (64%) and 27 female (36%). The mean course of irinotecan administered was 9.58. ABCG2 A421C had better overall survival in AC and CC genotype (median survival 23 ± 2.2 month and 26 ± 2.4 month, respectively) compared to those of AA genotype (median survival 8 ± 0.4 month, p = .002). TS G12C in 2R/3R was associate with an increased rate of grade 3 neutropenia in GC genotype (p = .048). MTHFR C677T was associate with an increased rate of grade 2 elevation of alanine aminotransferase in GC genotype (p = .044). Conclusion. These biomarkers could help to select the better treatment by reducing toxicity associated with irinotecan-based chemotherapy in metastatic colorectal cancer patients, and may improve their survival. |
本系統中英文摘要資訊取自各篇刊載內容。